Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 44Other hematologic neoplasm 42Sarcoma 5Myeloid 5Genitourinary 4Plasma cell 2Head & Neck 2Classical hematology 2CNS 2Thoracic 1Other neoplasm 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Cisplatin 85pembrolizumab 76Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Specimen Handling 36Cetuximab 36Carboplatin 35Radiotherapy 34Nivolumab 28Paclitaxel 24Radiation 22Platinum 22Docetaxel 20Biopsy 201,2-diaminocyclohexaneplatinum II citrate 20Gemcitabine 19Surveys and Questionnaires 15Fluorouracil 14toripalimab 13Standard of Care 12Taxes 11cemiplimab 9atezolizumab 9Ipilimumab 9Drug Therapy 9Cyclophosphamide 9X-Rays 8Surgical Procedures, Operative 8Radiosurgery 7Immunoglobulin G 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Methotrexate × Head & Neck × 90 days × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07361133 2026-04-16

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

National Cancer Institute, Egypt

Phase 2 Not yet recruiting
120 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡